Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe N. Amaria, Amir A. Jazaeri, Ying Yuan et al.|Journal for ImmunoTherapy of Cancer|2024Cited by 54
A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.Lauren Cobb, Amir A. Jazaeri, Joseph Davis et al.|Journal of Clinical Oncology|2022Cited by 34
Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated CancersVan K. Morris, Michael Frumovitz, Amir A. Jazaeri et al.|The Oncologist|2023Cited by 29
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancerEmily Hinchcliff, Amir A. Jazaeri, Anne Knisely et al.|Cancer|2023Cited by 18
Phase II trial of MEDI0457 and durvalumab for patients with recurrent/metastatic HPV-associated cancers.Van K. Morris, Amir A. Jazaeri, Shannon N. Westin et al.|Journal of Clinical Oncology|2021Cited by 8